RemeGen Announces Discloseable Transaction: Major Wealth Management Product Purchases with SPDB Yantai Branch
Key Highlights
- RemeGen Co., Ltd. has approved the use of up to RMB2.5 billion of idle self-owned funds for cash management through wealth management products.
- Between April and June 2026, RemeGen entered into a series of significant wealth management product agreements with SPDB Yantai Branch, aggregating to a substantial investment in structured deposits.
- On June 1, 2026, the company executed its largest single agreement in this series, SPDB Wealth Management Product Agreement No. 8, committing RMB300 million in idle self-owned funds.
- The agreements are considered discloseable transactions under Chapter 14 of the Hong Kong Listing Rules, as the aggregated transaction size exceeds 5% of the relevant percentage ratios.
Details of Wealth Management Product Purchases
At the 36th board meeting on March 27, 2026, RemeGen’s board resolved to enhance capital efficiency by investing idle funds in wealth management products. The strategy is designed to yield returns higher than traditional time deposits while maintaining a low-to-medium risk profile.
The company has since entered into eight agreements with SPDB Yantai Branch, of which the most recent and largest is:
- SPDB Wealth Management Product Agreement No. 8 (June 1, 2026)
- Product Name: Liduoduo Corporate Stable Profit 26JG7791 (Three-Tier Bullish) RMB Corporate Structured Deposit
- Principal: RMB300 million
- Term: 90 days (June 1, 2026 – August 31, 2026)
- Expected Annualized Yield: 0.7% or 1.8% or 2% (floating, principal-guaranteed)
- Linked to: EUR-USD exchange rate
- Early Termination: At SPDB Yantai Branch’s discretion
Other recent agreements (April–May 2026) include additional placements of RMB220 million, RMB80 million, RMB200 million, RMB100 million, and RMB100 million, with both self-owned funds and idle raised proceeds utilized.
Implications for Shareholders and Potential Impact on Share Price
- The transactions are aggregated for regulatory reporting purposes, with the total exceeding 5% but remaining under 25% of the applicable percentage ratios. This triggers a “discloseable transaction” status, leading to public reporting and announcement obligations.
- Price sensitivity: The deployment of a large amount of idle funds (over RMB1 billion across multiple agreements) into relatively low-risk, principal-guaranteed products may reassure investors about efficient capital utilization and prudent treasury management.
- Yield enhancement: The expected returns, which are higher than time deposits, could marginally improve the company’s financial income and bottom line, potentially supporting shareholder value.
- Risk Control: The company emphasizes strict investment risk control and the selection of low-to-medium risk products.
- Liquidity and Flexibility: The short-term nature (90-day maturity) ensures funds remain relatively liquid, minimizing long-term lock-up risk.
- Counterparty: All transactions are with the reputable Shanghai Pudong Development Bank (SPDB), reducing counterparty risk.
- There is a clause allowing the bank to terminate early, which shareholders should monitor for any potential impact on returns or timing of fund availability.
Background on RemeGen
RemeGen is a commercial-ready biopharmaceutical company focused on innovative therapies for autoimmune, oncology, and ophthalmic diseases, with a dual listing in Hong Kong and Shanghai.
Summary of Agreements
- No. 1: RMB220 million (April 28, 2026)
- No. 4: RMB80 million (May 6, 2026, using idle raised proceeds)
- No. 5: RMB200 million (May 6, 2026)
- No. 6: RMB100 million (May 11, 2026)
- No. 7: RMB100 million (May 13, 2026)
- No. 8: RMB300 million (June 1, 2026)
Conclusion
Investor Takeaway: RemeGen’s strategic deployment of idle funds into bank-structured deposits demonstrates the company’s commitment to maximizing capital utilization while maintaining prudent risk management. The size and aggregated nature of these transactions are material enough to warrant attention, as they may incrementally affect the company’s financial profile and share value. Investors should stay alert to further disclosures, especially regarding product yields and any early terminations exercised by SPDB Yantai Branch.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The company’s actual financial performance and share price may be affected by factors beyond those discussed above.
榮昌生物公佈重大財務動向：與浦發銀行煙台分行大額理財產品投資詳情
重點摘要
- 榮昌生物（RemeGen）已批准動用最多人民幣25億元的閒置自有資金進行理財產品投資。
- 2026年4月至6月期間，公司與浦發銀行煙台分行簽訂一系列重大理財產品協議，總投資額非常可觀，主要用於結構性存款。
- 2026年6月1日，公司進行了本系列中最大單筆投資——理財產品協議第8號，動用人民幣3億元閒置自有資金。
- 根據香港上市規則第14章，該等交易屬於“須予披露交易”，因為合計規模超過相關百分比比率的5%。
理財產品投資詳情
2026年3月27日，第36屆董事會會議通過決議，利用閒置資金購買理財產品以提升資金使用效率，目標是實現高於傳統定期存款的回報，同時保持低至中等風險。
公司自此與浦發銀行煙台分行簽訂了八份協議，其中最新、最大的一單如下：
- 理財產品協議第8號（2026年6月1日）
- 產品名稱：利多多公司穩利26JG7791（三層看漲）人民幣結構性存款
- 本金：人民幣3億元
- 期限：90天（2026年6月1日至8月31日）
- 預期年化收益率：0.7%或1.8%或2%（保本浮動收益）
- 掛鈎標的：歐元兌美元匯率
- 提前終止權：由浦發銀行煙台分行決定
其他近期協議（2026年4月至5月）還包括2.2億元、8,000萬元、2億元、1億元、1億元等投入，分別來自自有資金及閒置募集資金。
對股東的重要事項和潛在股價影響
- 該等交易根據上市規則需合併計算，合計金額突破5%，但不到25%，構成“須予披露交易”，公司必須公開披露。
- 價格敏感因素：大額閒置資金（累計超過人民幣10億元）投向低風險保本理財，有助於提升資金使用效率，展現審慎財務管理，對投資者屬正面訊號。
- 收益提升：所選產品預期回報優於同期定存，有望為公司帶來額外財務收入，支持公司價值。
- 風控：公司強調嚴格控制投資風險，選擇低至中風險產品。
- 流動性：投資產品期限較短（90天），資金流動性高，減低長期鎖定風險。
- 對手方：所有協議均與國有上市銀行浦發銀行簽署，對手風險較低。
- 產品條款包括銀行可提前終止，股東需關注該條款是否影響收益或資金提取時點。
公司背景簡介
榮昌生物是一家專注自身免疫、腫瘤及眼科創新藥物的商業化生物製藥公司，於香港及上海兩地上市。
協議摘要
- 第1號：人民幣2.2億元（2026年4月28日）
- 第4號：人民幣8,000萬元（2026年5月6日，使用閒置募集資金）
- 第5號：人民幣2億元（2026年5月6日）
- 第6號：人民幣1億元（2026年5月11日）
- 第7號：人民幣1億元（2026年5月13日）
- 第8號：人民幣3億元（2026年6月1日）
總結
投資者須知：公司積極運用閒置資金進行短期銀行理財，體現資金運用效率和審慎風控。交易規模足以對公司財務狀況及股價構成潛在影響，建議股東密切留意後續披露，特別是產品實際收益及銀行是否提前終止。
免責聲明
本文僅供參考，並不構成投資建議。投資者應自行調查並諮詢專業顧問，才作出投資決策。公司實際經營及股價可能受多種因素影響。
